Adrenalectomy for Cushing's Syndrome: Do's and Don'ts
Overview
Authors
Affiliations
To present specific aspects of adrenalectomy for Cushing's syndrome (CS) by introducing well established aspects ("do's") and less known aspects ("don'ts"). This is a narrative review. The "do's" for laparoscopic adrenalectomy (LA) are the following: it represents the "gold standard" for secretor and non-secretor adrenal tumors and the first line therapy for CS with an improvement of cardio-metabolic co-morbidities; the success rate depending on the adequate patients' selection and the surgeon's skills. The "don'ts" are large (>6-8 centimeters), locally invasive, malignant tumors requiring open adrenalectomy (OA). Robotic adrenalectomy is a new alternative for LA, with similar safety and conversion rate and lower pain drugs use. The "don'ts" are the following: lack of randomized controlled studies including oncologic outcome, different availability at surgical centers. Related to the sub-types of CS, the "do's" are the following: adrenal adenomas which are cured by LA, while adrenocortical carcinoma (ACC) requires adrenalectomy as first line therapy and adjuvant mitotane therapy; synchronous bilateral adrenalectomy (SBA) is useful for Cushing's disease (only cases refractory to pituitary targeted therapy), for ectopic Cushing's syndrome (cases with unknown or inoperable primary site), and for bilateral cortisol producing adenomas. The less established aspects are the following: criteria of skilled surgeon to approach ACC; the timing of surgery in subclinical CS; the need for adrenal vein catheterization (which is not available in many centers) to avoid unnecessary SBA. Adrenalectomy for CS is a dynamic domain; LA overstepped the former OA area. The future will improve the knowledge related to RA while the cutting edge is represented by a specific frame of intervention in SCS, children and pregnant women. ACC = adrenocortical carcinoma, ACTH = Adrenocorticotropic Hormone, CD = Cushing's disease, CS = Cushing's syndrome, ECS = Ectopic Cushing's syndrome, LA = laparoscopic adrenalectomy, OA = open adrenalectomy, PA = partial adrenalectomy, RA = robotic adrenalectomy, SCS = subclinical Cushing' syndrome.
The Entity of Connshing Syndrome: Primary Aldosteronism with Autonomous Cortisol Secretion.
Carsote M Diagnostics (Basel). 2022; 12(11).
PMID: 36428832 PMC: 9689802. DOI: 10.3390/diagnostics12112772.
Approach of Heterogeneous Spectrum Involving 3beta-Hydroxysteroid Dehydrogenase 2 Deficiency.
Nicola A, Carsote M, Gheorghe A, Petrova E, Popescu A, Staicu A Diagnostics (Basel). 2022; 12(9).
PMID: 36140569 PMC: 9497988. DOI: 10.3390/diagnostics12092168.
Essien F, Persaud C, Dado D, Eden R, Tate J, Shahin G Clin Case Rep. 2021; 9(12):e05168.
PMID: 34938550 PMC: 8666948. DOI: 10.1002/ccr3.5168.
Melanoma in patients with Li-Fraumeni syndrome (Review).
Sandru F, Dumitrascu M, Petca A, Carsote M, Petca R, Ghemigian A Exp Ther Med. 2021; 23(1):75.
PMID: 34934446 PMC: 8652386. DOI: 10.3892/etm.2021.10998.
Adrenal ganglioneuroma: Prognostic factors (Review).
Sandru F, Dumitrascu M, Petca A, Carsote M, Petca R, Oproiu A Exp Ther Med. 2021; 22(5):1338.
PMID: 34630692 PMC: 8495554. DOI: 10.3892/etm.2021.10773.